RU2004111358A - Комбинированные агенты для лечения глаукомы - Google Patents

Комбинированные агенты для лечения глаукомы Download PDF

Info

Publication number
RU2004111358A
RU2004111358A RU2004111358/15A RU2004111358A RU2004111358A RU 2004111358 A RU2004111358 A RU 2004111358A RU 2004111358/15 A RU2004111358/15 A RU 2004111358/15A RU 2004111358 A RU2004111358 A RU 2004111358A RU 2004111358 A RU2004111358 A RU 2004111358A
Authority
RU
Russia
Prior art keywords
treatment
glaucoma
prevention
combination
active ingredients
Prior art date
Application number
RU2004111358/15A
Other languages
English (en)
Inventor
Томихиса ЙОКОЯМА (JP)
Томихиса ЙОКОЯМА
Original Assignee
Санкио Компани, Лимитед (Jp)
Санкио Компани, Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санкио Компани, Лимитед (Jp), Санкио Компани, Лимитед filed Critical Санкио Компани, Лимитед (Jp)
Publication of RU2004111358A publication Critical patent/RU2004111358A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Claims (6)

1. Комбинация для профилактики или лечения глаукомы, которая включает антагонист ангиотензина II и дорзоламида или его фармацевтически приемлемой соли в качестве активных ингредиентов, для одновременного, раздельного или последовательного использования указанных активных ингредиентов, где антагонист ангиотензина II представляет собой соединение формулы (I) или его фармакологически приемлемую соль, сложный эфир или другое производное:
Figure 00000001
где R1 представляет группу, имеющую структурную формулу (Ia), (Ib) или (Ic):
Figure 00000002
2. Комбинация для профилактики или лечения глаукомы по п. 1, в которой R1 представляет группу, имеющую формулу (Ia).
3. Комбинация для профилактики или лечения глаукомы по любому из пп. 1 и 2, в которой указанная фармацевтически приемлемая соль дорзоламида представляет собой дорзоламида гидрохлорид.
4. Комбинация для профилактики или лечения глаукомы по любому из пп. 1 и 2, которая находится в форме, удобной для местного нанесения в глаза.
5. Комбинация для профилактики или лечения глаукомы по любому из п. 3, которая находится в форме, удобной для местного нанесения в глаза.
6. Способ профилактики или лечения глаукомы, который включает введение пациенту комбинации для профилактики или лечения глаукомы по любому из пп. 1-5.
RU2004111358/15A 1999-12-01 2004-04-13 Комбинированные агенты для лечения глаукомы RU2004111358A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP34152499 1999-12-01
JP11/341524 1999-12-01
JP2000-78769 2000-03-21
JP2000078769 2000-03-21

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2002114335/15A Division RU2002114335A (ru) 1999-12-01 2000-12-01 Комбинированные агенты для лечения глаукомы

Publications (1)

Publication Number Publication Date
RU2004111358A true RU2004111358A (ru) 2005-09-20

Family

ID=26576988

Family Applications (4)

Application Number Title Priority Date Filing Date
RU2002114335/15A RU2002114335A (ru) 1999-12-01 2000-12-01 Комбинированные агенты для лечения глаукомы
RU2004111359/15A RU2004111359A (ru) 1999-12-01 2004-04-13 Комбинированные агенты для лечения глаукомы
RU2004111358/15A RU2004111358A (ru) 1999-12-01 2004-04-13 Комбинированные агенты для лечения глаукомы
RU2004111357/15A RU2299067C2 (ru) 1999-12-01 2004-04-13 Комбинированные агенты для лечения глаукомы

Family Applications Before (2)

Application Number Title Priority Date Filing Date
RU2002114335/15A RU2002114335A (ru) 1999-12-01 2000-12-01 Комбинированные агенты для лечения глаукомы
RU2004111359/15A RU2004111359A (ru) 1999-12-01 2004-04-13 Комбинированные агенты для лечения глаукомы

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2004111357/15A RU2299067C2 (ru) 1999-12-01 2004-04-13 Комбинированные агенты для лечения глаукомы

Country Status (22)

Country Link
US (4) US7307096B2 (ru)
EP (3) EP1344535A3 (ru)
JP (1) JP4000505B2 (ru)
KR (3) KR20040045029A (ru)
CN (3) CN1263512C (ru)
AT (1) ATE332145T1 (ru)
AU (1) AU773110B2 (ru)
BR (1) BR0015980A (ru)
CA (1) CA2392804C (ru)
CZ (1) CZ20021829A3 (ru)
DE (1) DE60029242T2 (ru)
ES (1) ES2267586T3 (ru)
HK (1) HK1047239B (ru)
HU (1) HUP0204049A3 (ru)
IL (2) IL149444A0 (ru)
MX (1) MXPA02005505A (ru)
NO (1) NO20022584L (ru)
NZ (1) NZ518930A (ru)
PL (1) PL201783B1 (ru)
RU (4) RU2002114335A (ru)
TW (1) TWI290470B (ru)
WO (1) WO2001039805A1 (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0209063A (pt) * 2001-04-19 2004-08-10 Teika Pharmaceutical Co Ltd Medicamentos e kits de uso medicinal
TW200305424A (en) 2002-01-29 2003-11-01 Santen Pharmaceutical Co Ltd Glaucoma-treating agent comprising bunazosin and prostaglandin
US20050119299A1 (en) * 2002-03-08 2005-06-02 Sankyo Company, Limited Ophthalmic solutions containing tetrazole derivatives
US8580851B2 (en) 2002-08-21 2013-11-12 Sucampo Ag Ophthalmic solution
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
EP2404606A1 (en) * 2003-08-21 2012-01-11 Sucampo AG Ophthalmic compositions comprising a prostaglandin and a viscosity agent
WO2005079809A1 (ja) * 2004-02-19 2005-09-01 Santen Pharmaceutical Co., Ltd. 澄明なラタノプロスト点眼液
JP2005263792A (ja) * 2004-02-19 2005-09-29 Santen Pharmaceut Co Ltd 澄明なラタノプロスト点眼液
CN101400354B (zh) * 2006-03-13 2014-10-22 株式会社·R-技术上野 水性组合物
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
CN102970973A (zh) * 2010-05-07 2013-03-13 太阳医药高级研发有限公司 新型眼用组合物
RU2443416C2 (ru) * 2010-05-17 2012-02-27 Республиканское Унитарное производственное предприятие "Белмедпрепараты" Капли глазные
WO2012100347A1 (en) * 2011-01-24 2012-08-02 Inceptum Research & Therapeutics, Inc. Compositions comprising a prostaglandin for treating neuropsychiatric conditions
KR101327267B1 (ko) 2012-04-26 2013-11-11 한양대학교 에리카산학협력단 엔드이펙터용 구동력 전달장치
CA2968926C (en) * 2014-11-25 2023-01-17 Izhar Halahmi Compositions and methods for delivering a bio-active agent or bio-active agents
WO2016093346A1 (ja) * 2014-12-12 2016-06-16 興和株式会社 水性組成物

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3619370A (en) 1969-04-21 1971-11-09 Frosst & Co Charles E Microbial reduction of thiadiazoles
JPS4966691A (ru) 1972-10-30 1974-06-27
IE50901B1 (en) * 1980-03-04 1986-08-06 Merck & Co Inc Ophthalmic compositions of carbonic anhydrase inhibitors for topical application in the treatment of elevated intraocular pressure
US4394382A (en) 1980-06-17 1983-07-19 Kowa Company, Ltd. Dihydrobenzopyran compounds and pharmaceutical composition comprising said compounds
US4863922A (en) 1984-12-12 1989-09-05 Merck & Co., Inc. Substituted aromatic sulfonamides as antiglaucoma agents, compositions and use
DE3568431D1 (en) * 1984-12-12 1989-04-06 Merck & Co Inc Substituted aromatic sulfonamides, their preparation and ophthalmic compositions containing them
US5182264A (en) * 1986-03-07 1993-01-26 Schering Corporation Angiotensin II receptor blockers as antiglaucoma agents
JP2610619B2 (ja) * 1987-07-22 1997-05-14 エーザイ株式会社 高眼圧症治療用点眼剤
JPS6426518U (ru) 1987-08-11 1989-02-15
ES2213504T1 (es) 1988-09-06 2004-09-01 Pfizer Health Ab Derivados de prostaglandina para el tratamiento del glaucoma o hipertension ocular.
WO1990002533A2 (de) 1988-09-09 1990-03-22 Klaus Draenert Hüftgelenksprothese und ihre verwendung
EP0375299A1 (en) * 1988-12-19 1990-06-27 Merck & Co. Inc. Combinations of angiotensin converting enzyme, and carbonic anhydrase, inhibitors for treating glaucoma
US5273976A (en) * 1989-04-06 1993-12-28 Sankyo Company, Limited Ocular hypotensive agents
US5175161A (en) * 1989-04-06 1992-12-29 Sankyo Company, Limited Occular hypotensive agents
WO1991015206A1 (en) * 1990-04-05 1991-10-17 E.I. Du Pont De Nemours And Company Treatment of glaucoma and ocular hypertension with imidazole angiotensin-ii receptor antagonists
CA2057089A1 (en) * 1990-12-07 1992-06-08 Eric E. Allen Substituted pyrazolopyrimidines and imidazopyridazines as angiotensin ii antagonists
US5250521A (en) 1990-12-07 1993-10-05 Merck & Co., Inc. Substituted pyrazolopyrimidines as angiotensin II antagonists
NZ242724A (en) * 1991-05-15 1994-09-27 Du Pont Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker
IL104648A0 (en) 1992-02-13 1993-06-10 Merck & Co Inc Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a prostaglandin or prostaglandin derivative
DK0625903T3 (da) * 1992-02-21 1999-05-10 Alcon Lab Inc Topiske antiglaukompræparater omfattende carbonsyreanhydraseinhibitorer og beta-blokkere
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
CZ154994A3 (en) * 1993-07-02 1995-09-13 Senju Pharma Co Visual hypotensive agent
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
CA2181461A1 (en) * 1994-02-08 1995-08-17 Alica Huxley Treatment of normotensive glaucoma with angiotensin ii antagonists
RU2123847C1 (ru) * 1994-03-16 1998-12-27 Санкио Компани Лимитед Лекарственное средство и способ лечения повышенного глазного давления и/или глаукомы
CA2185524C (en) * 1994-03-16 2006-12-05 Tomihisa Yokoyama Ocular tension depressant
US5760249A (en) * 1995-08-29 1998-06-02 Merck & Co., Inc. Synthesis of hydroxysulfone and related compounds
US5741810A (en) 1996-02-29 1998-04-21 Allergan Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents
KR19990087076A (ko) * 1996-04-05 1999-12-15 다께다 구니오 안지오텐신 ⅱ 및 길항 활성을 갖는 화합물을 함유하는 약제학적 배합물
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
US6037368A (en) 1997-05-09 2000-03-14 Mount Sinai School Of Medicine 8-iso- prostaglandins for glaucoma therapy
PL200009B1 (pl) * 1999-06-11 2008-11-28 Sankyo Co Kompozycja obniżająca ciśnienie wewnątrzgałkowe oraz zastosowanie antagonisty angiotensyny II do obniżania ciśnienia wewnątrzgałkowego

Also Published As

Publication number Publication date
HK1047239B (zh) 2006-12-08
JP4000505B2 (ja) 2007-10-31
CA2392804A1 (en) 2001-06-07
JP2001335511A (ja) 2001-12-04
EP1234582A1 (en) 2002-08-28
RU2002114335A (ru) 2004-01-10
ATE332145T1 (de) 2006-07-15
KR20040045029A (ko) 2004-05-31
EP1344535A3 (en) 2004-01-28
EP1344534A2 (en) 2003-09-17
EP1234582A4 (en) 2003-05-07
HK1047239A1 (en) 2003-02-14
RU2004111357A (ru) 2005-09-20
DE60029242T2 (de) 2007-07-05
US20050043383A1 (en) 2005-02-24
EP1344534A3 (en) 2004-01-02
HUP0204049A3 (en) 2006-07-28
DE60029242D1 (de) 2006-08-17
CN1615880A (zh) 2005-05-18
CN1407903A (zh) 2003-04-02
US7307096B2 (en) 2007-12-11
AU773110B2 (en) 2004-05-20
KR20020058034A (ko) 2002-07-12
EP1344535A2 (en) 2003-09-17
AU1557501A (en) 2001-06-12
BR0015980A (pt) 2002-11-12
NO20022584L (no) 2002-07-29
CN1615879A (zh) 2005-05-18
PL201783B1 (pl) 2009-05-29
HUP0204049A2 (hu) 2003-04-28
US20080221184A1 (en) 2008-09-11
CN1263512C (zh) 2006-07-12
TWI290470B (en) 2007-12-01
CA2392804C (en) 2009-02-03
KR100607430B1 (ko) 2006-08-02
CZ20021829A3 (cs) 2002-08-14
WO2001039805A1 (fr) 2001-06-07
PL355431A1 (en) 2004-04-19
IL149444A (en) 2007-06-17
ES2267586T3 (es) 2007-03-16
US20030040529A1 (en) 2003-02-27
IL149444A0 (en) 2002-11-10
KR20040045028A (ko) 2004-05-31
RU2299067C2 (ru) 2007-05-20
EP1234582B1 (en) 2006-07-05
RU2004111359A (ru) 2005-09-20
MXPA02005505A (es) 2002-09-02
US20050014808A1 (en) 2005-01-20
NZ518930A (en) 2003-09-26
NO20022584D0 (no) 2002-05-31

Similar Documents

Publication Publication Date Title
RU2004111358A (ru) Комбинированные агенты для лечения глаукомы
JP5174777B2 (ja) Ｒｈｏキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤
JP4934653B2 (ja) Ｒｈｏキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤
LU92058I2 (fr) Travoprost et ses sels pharmaceutiquement acceptables (TRAVATAN®)
ES2295609T3 (es) Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor.
RU2004110719A (ru) Зздабиторы протеаз, расщепляющих за пролином
LU90956I2 (fr) Metvix principe actif méthylaminolevulinique sous forme d'un selde préférence l'hyhrochlorure méthylaminolevulinique
RU2002117649A (ru) Фармацевтические композиции, содержащие золмитриптан
EA200401301A1 (ru) Полициклические соединения как эффективные антагонисты альфа-2 адренорецептора
SE0102055D0 (sv) New Compounds
JP2004107335A (ja) Ｒｈｏキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤
RU2000122435A (ru) Производные индола и фармацевтические композиции, включающие их
DK1458393T3 (da) Substituerede diketopiperaziner som oxytocinantagonister
HK1061645A1 (en) 3, 7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
JP2005513103A5 (ru)
KR960034190A (ko) N-아실피페라진 유도체 및 항균제, 항궤양제
RU2005135647A (ru) Комбинации, включающие пароксетин и {1-(r)-(3.5-бис-трифтор-2-метилфенил) этилметиламид}-2-(s)-(4-фтор-2-метилфенил) пиперазин-1-карбоновой кислоты, для лечения депрессии и/или тревоги
ES2140531T3 (es) Inhibidor de la interleucina-1.
RU2003104017A (ru) Ингибиторы тромбина, содержащие аминоизохинолиновую группу
RU2004129767A (ru) Хинолиновые производные
RU2227740C2 (ru) Композиции, снижающие внутриглазное давление, для местного применения
TWI809021B (zh) 含有ＦＰ促效藥及β阻斷藥的青光眼治療劑
WO2005021040A3 (en) Compositions useful for treating gastrointestinal motility disorders
ATE215824T1 (de) Mittel zur verminderung des augeninnendrucks
KR920019767A (ko) 티아졸 유도체

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20060418